BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32787475)

  • 1. Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232.
    Villa-Ruano N; Guerrero-González T; Gómez-Conde E; Perez-Santos M
    Expert Opin Ther Pat; 2020 Oct; 30(10):723-727. PubMed ID: 32787475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.
    Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L; Rosas-Murrieta NH
    Expert Opin Ther Pat; 2019 Dec; 29(12):921-924. PubMed ID: 31627712
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.
    Herrera-Camacho I; Anaya-Ruiz M; Perez-Santos M; Millán-Pérez Peña L; Bandala C; Landeta G
    Expert Opin Ther Pat; 2019 Aug; 29(8):587-593. PubMed ID: 31241380
    [No Abstract]   [Full Text] [Related]  

  • 4. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054.
    Cebada J; Flores A; Bandala C; Lizaliturri-Flores I; Villa-Ruano N; Perez-Santos M
    Expert Opin Ther Pat; 2020 Jul; 30(7):487-494. PubMed ID: 32397849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.
    Hellmann MD; Bivi N; Calderon B; Shimizu T; Delafontaine B; Liu ZT; Szpurka AM; Copeland V; Hodi FS; Rottey S; Aftimos P; Piao Y; Gandhi L; Galvao VR; Leow CC; Doi T
    Clin Cancer Res; 2021 May; 27(10):2773-2781. PubMed ID: 33441294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials.
    Kiem D; Ocker M; Greil R; Neureiter D; Melchardt T
    Expert Opin Investig Drugs; 2024 Mar; 33(3):229-242. PubMed ID: 38354028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
    Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
    Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
    Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
    Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
    Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).
    Shaabani S; Huizinga HPS; Butera R; Kouchi A; Guzik K; Magiera-Mularz K; Holak TA; Dömling A
    Expert Opin Ther Pat; 2018 Sep; 28(9):665-678. PubMed ID: 30107136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
    Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
    J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
    Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
    Front Immunol; 2021; 12():654080. PubMed ID: 34040604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.
    Cui X; Jia H; Xin H; Zhang L; Chen S; Xia S; Li X; Xu W; Chen X; Feng Y; Wei X; Yu H; Wang Y; Zhan Y; Zhu X; Zhang X
    Front Immunol; 2021; 12():778978. PubMed ID: 34925354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1.
    Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L
    Expert Opin Ther Pat; 2019 Jul; 29(7):481-485. PubMed ID: 31216214
    [No Abstract]   [Full Text] [Related]  

  • 17. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
    Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
    Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536.
    Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Rosas-Murrieta NH; Millán-Pérez Peña L
    Expert Opin Ther Pat; 2020 Feb; 30(2):83-86. PubMed ID: 31874056
    [No Abstract]   [Full Text] [Related]  

  • 19. Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors.
    Perez-Santos M
    Pharm Pat Anal; 2020 Sep; 9(5):149-154. PubMed ID: 32960139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.
    Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J
    Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.